<DOC>
	<DOCNO>NCT01986101</DOCNO>
	<brief_summary>The study evaluate efficacy safety SM-13496 compare placebo patient Bipolar I Depression .</brief_summary>
	<brief_title>A Phase III Study SM-13496 Patients With Bipolar I Depression .</brief_title>
	<detailed_description>The primary objective compare efficacy SM-13496 ( 20-60 80-120 mg/day ) monotherapy placebo patient depressive symptom associate bipolar I disorder assess change baseline MADRS total score Week 6 .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Patients fully inform understand objective , procedure , possible benefit risk study provide write voluntary consent participate study . Outpatients age 18 74 year time consent Patients meet DSMIVTR criterion bipolar I disorder , recent episode depress ( â‰¥ 4 week less 12 month ) without psychotic feature . Patients imminent risk suicide injury self , others , property . Patients hospitalize manic mixed episode within 60 day prior screen . Patients otherwise consider ineligible study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>